8-K: CervoMed Data Shows Neflamapimod Reverses Brain Volume Loss in DLB

CervoMed announced new data from its Phase 2b RewinD-LB trial, indicating neflamapimod increased basal forebrain volume and functional connectivity in patients with dementia with Lewy bodies.

Summary

• CervoMed presented new data from its Phase 2b RewinD-LB trial at the 2026 American Academy of Neurology (AAN) Annual Meeting.
• The data demonstrated that neflamapimod increased basal forebrain (BF) volume and functional connectivity in patients with dementia with Lewy bodies (DLB).
• These findings are consistent with preclinical studies suggesting that basal forebrain atrophy in DLB may be reversible.
• The study showed a statistically significant increase in right BF volume (p=0.022 vs. placebo) and a numerical advantage in Nucleus basalis of Meynert (NbM) volume at week 16.
• Functional connectivity between the right BF and the default mode network (DMN) significantly increased during the extension period (p=0.019 vs. start of extension).
• An inverse correlation was observed between increased functional connectivity and reduction in CDR-SB scores (p=0.027).
• DLB is the second most common progressive dementia, affecting millions worldwide, with no approved treatments in the US or EU.
• CervoMed plans to initiate a global, pivotal Phase 3 trial in DLB patients in the second half of 2026, subject to financing.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to statistically significant improvements in key biomarkers and functional connectivity, with a clear path towards Phase 3, though financing remains a key dependency.

Positives

• Demonstrated statistically significant increase in right basal forebrain (BF) volume at week 16 (p=0.022 vs. placebo).
• Showed a numerical advantage in Nucleus basalis of Meynert (NbM) volume at week 16.
• Observed a significant increase in right BF to default mode network (DMN) static functional connectivity during the extension period (p=0.019).
• Found an inverse correlation between increased functional connectivity and improvement in CDR-SB scores (p=0.027).
• Results are consistent with preclinical data suggesting reversibility of basal forebrain atrophy in DLB.
• Neflamapimod has been generally well-tolerated in over 800 participants across previous trials.
• The drug readily crosses the blood-brain barrier and targets key disease processes in neuroinflammation and synaptic dysfunction.
• The company plans to initiate a pivotal Phase 3 trial in DLB patients.

Negatives

• No differences in volumetric or functional connectivity measures were seen on the left side of the brain.
• The placebo group showed a decrease in right BF volume at week 16.
• The Phase 2b trial involved a small number of patients (8 neflamapimod treated and 10 placebo recipients during the initial 16-week period).
• The Phase 3 trial initiation is subject to financing.

Risks

• The initiation of the planned Phase 3 trial is subject to financing.
• Actual results of clinical trials could differ materially from forward-looking statements due to known and unknown risks and uncertainties.
• The Company's ability to continue as a going concern is dependent on securing additional funds.
• Regulatory approval of neflamapimod is not guaranteed, and feedback from the FDA may differ from expectations.
• General economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts could impact the Company's operations and development plans.

Future Outlook

CervoMed plans to initiate a global, pivotal Phase 3 trial in DLB patients, enriched for those without AD co-pathology, in the second half of 2026, subject to financing. The company anticipates that neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression in DLB.

Management Comments

• "These findings from further analysis of the RewinD-LB Phase 2b clinical trial are consistent with preclinical data, including prior studies with neflamapimod, which show that basal forebrain atrophy in DLB might be reversible."
• "Importantly, the study showed that changes in volume coincide with functional brain changes. This could indicate that the observed treatment-related forebrain volume changes in DLB could reflect a resolution of synaptic dysfunction and cellular shrinkage. If proven to be the case, this could change our perspective on neuroprotection or even reversal of volume loss."
• "Therapies such as neflamapimod that target basal forebrain cholinergic dysfunction and degeneration can teach us something new about the brain, and especially brain volume changes in conditions like DLB."
• "Combining structural and functional outcomes creates the opportunity to detect treatment effects over shorter timeframes and in smaller studies, and supports the use of basal forebrain MRI as a sensitive biomarker in disease such as DLB that have prominent cholinergic deficits."
• "Atrophy in the basal forebrain is an important driver of clinical symptoms and progression of DLB. Combined with our previously reported data in neflamapimod treated-patients with early AD, where we saw very similar effects on the basal forebrain, these MRI analyses provide strong evidence that neflamapimod is acting on the underlying cause of DLB by reducing basal forebrain atrophy, reinforcing our clinical and biomarker data and enhancing our belief that neflamapimod has the potential to make a meaningful difference for patients with DLB."
• "We look forward to incorporating this technology into our planned Phase 3 trial in DLB patients which, subject to financing, we plan to start later this year."

Industry Context

StockSavvy.ai notes that the positive results for neflamapimod in DLB, particularly the potential for reversing brain volume loss and improving functional connectivity, are significant in a therapeutic area with no approved treatments. This aligns with the broader industry trend of seeking disease-modifying therapies rather than just symptomatic relief for neurodegenerative conditions.

Stakeholder Impact

• Shareholders: Potential for increased company valuation if neflamapimod proves successful in Phase 3 trials and gains regulatory approval.
• Patients with DLB: Hope for a potential new treatment option for a disease with no current approved therapies.
• Medical Community: New insights into the potential reversibility of DLB pathology and the utility of MRI as a biomarker.
• Creditors/Investors: The need for financing for the Phase 3 trial introduces financial risk and potential dilution.

Next Steps

• Initiate a global, pivotal Phase 3 trial in DLB patients (subject to financing) in the second half of 2026.
• Incorporate MRI technology into the planned Phase 3 trial.
• Continue to seek financing for the Phase 3 trial.

Key Dates

Recommendation

The data presented is promising, showing positive biomarker and functional connectivity results in a difficult-to-treat indication. However, the critical dependency on future financing for the pivotal Phase 3 trial introduces significant uncertainty, warranting a 'hold' position until funding is secured and Phase 3 initiation is confirmed.

Keywords

Dementia with Lewy Bodies, Neflamapimod, CervoMed, Phase 2b Trial, Basal Forebrain, Neuroinflammation, Synaptic Dysfunction, Clinical Data